Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition

Cytokine

Volumn 72, Issue 1, 2015, Pages 43-47

  Sarray, Sameh ^a   Saleh, Layal R ^a   Lisa Saldanha, F ^a   Al Habboubi, Hebah H ^a   Mahdi, Najat ^b   Almawi, Wassim Y ^a  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

^b Department of Pediatrics ^*  (Bahrain)

Author keywords

Cytokine; Inflammation; Interleukin 10; Sickle cell disease; Vaso occlusive crisis

Indexed keywords

HYDROXYUREA; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TNF PROTEIN, HUMAN;

ARTICLE; BLOOD VESSEL OCCLUSION; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; SICKLE CELL ANEMIA; STEADY STATE; VASOOCCLUSIVE CRISIS; ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BLOOD; IMMUNOLOGY; INFANT; INFLAMMATION; PATHOPHYSIOLOGY; PRESCHOOL CHILD; VASCULAR DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROXYUREA; INFANT; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MALE; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES; YOUNG ADULT;

EID: 84920971115     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.11.030     Document Type: Article

References (36)

1. Conran N., Franco-Penteado C.F., Costa F.F. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin 2009, 33:1-16.
2. Mehanna A.S. Sickle cell anemia and antisickling agents then and now. Curr Med Chem 2001, 8:79-88.
3. Barabino G.A., Platt M.O., Kaul D.K. Sickle cell biomechanics. Annu Rev Biomed Eng 2010, 15(12):345-367.
4. Chiang E.Y., Frenette P.S. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005, 195:771-784.
5. Frenette P.S. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 2002, 92:101-106.
6. Platt O.S., Thorington B., Brambilla D.J., Milner P.F., Rosse W.F. Pain in sickle cell disease: rates and risk factors. N Engl J Med 1993, 325:11-16.
7. Platt O.S., Brambilla D.J., Rosse W.F., Milner P.F., Castro O., Steinberg M.H. Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994, 330:1639-1644.
8. Mohammed F.A., Mahdi N., Sater M.A., Al-Ola K., Almawi W.Y. The relation of C-reactive protein to vasoocclusive crisis in children with sickle cell disease. Blood Cells Mol Dis 2010, 45:293-296.
9. Bourantas K.L., Dalekos G.N., Makis A., Chaidos A., Tsiara S., Mavridis A. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 1998, 61:49-54.
10. Stuart J., Stone P.C.W., Akinola N.O., Gallimore J.R., Pepys M.B. Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. J Clin Pathol 1994, 47:166-169.
11. Lanaro C., Franco-Penteado C.F., Albuqueque D.M., Saad S.T., Conran N., Costa F.F. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 2009, 85:235-242.
12. Makis A.C., Hatzimichael E.C., Bourantas K.L. The role of cytokines in sickle cell disease. Ann Hematol 2000, 79:407-413.
13. Bandeira I.C., Rocha L.B., Barbosa M.C., Elias D.B., Querioz J.A., Freitas M.V., et al. Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype. Cytokine 2014, 65:217-221.
14. Malave I., Perdomo Y., Escalona E., Rodriguez E., Anchustegui M., Malavé H., et al. Level of tumor necrosis factor alpha/cachectin (TNF alpha) in sera from patients with sickle cell disease. Acta Haematol 1993, 90:172-176.
15. Keikhaei B., Mohseni A.R., Norouzirad R., Alinejadi M., Ghanbari S., Shiravi F., et al. Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. Eur Cytokine Netw 2013, 24:45-52.
16. Sabat R., Grutz G., Warszawska K., Kirsch S., Witte E., Wolk K., et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010, 21:331-344.
17. Hovsepian E., Penas F., Siffo S., Mirkin G.A., Goren N.B. IL-10 inhibits the NF-κB and ERK/MAPK-mediated production of pro-inflammatory mediators by up-regulation of SOCS-3 in Trypanosoma cruzi-infected cardiomyocytes. PLoS One 2013, 8:e79445.
18. Qian L., Hong J.S., Flood P.M. Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of interleukin 10. J Neural Transm Suppl 2006, 70:367-371.
19. Huet O., Laemmel E., Fu Y., Dupic L., Aprico A., Andrews K.L., et al. Interleukin 10 antioxidant effect decreases leukocytes/endothelial interaction induced by tumor necrosis factor α. Shock 2013, 39:83-88.
20. Bao W., Zhong H., Manwani D., Vasovic L., Uehlinger J., Lee M.T., et al. Regulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell disease. Am J Hematol 2013, 88:736-740.
21. Walter P.B., Fung E.B., Killilea D.W., et al. Oxidative stress and inflammation in iron-overloaded patients with beta thalassaemia or sickle cell disease. Br J Haematol 2006, 135:254-263.
22. Barbosa M.C., Dos Santos T.E., de Souza G.F., de Assis L.C., Freitas M.V., Gonçalves R.P. Impact of iron overload on interleukin-10 levels, biochemical parameters and oxidative stress in patients with sickle cell anemia. Rev Bras Hematol Hemoter 2013, 35:29-34.
23. Musa B.O., Onyemelukwe G.C., Hambolu J.O., Mamman A.I., Isa A.H. Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis. Clin Vaccine Immunol 2010, 17:602-608.
24. Bowers A.S., Reid H.L., Greenidge A., Landis C., Reid M. Blood viscosity and the expression of inflammatory and adhesion markers in homozygous sickle cell disease subjects with chronic leg ulcers. PLoS One 2013, 8:e68929.
25. Graido-Gonzalez E., Doherty J.C., Bergreen E.W., Organ G., Telfer M., McMillen M.A. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 1998, 92:2551-2555.
26. Sarray S., Mahdi N., Saleh L.R., Almaoui W.Y. Reduction in serum IL-10 levels is a surrogate marker for predicting vaso-occlusive crisis in sickle cell disease. Am J Hematol 2014 Jul, 89(7):789-790.
27. Gonsalves C.S., Kalra V.K. Hypoxia-mediated expression of 5-lipoxygenase-activating protein involves HIF-1alpha and NF-kappaB and microRNAs 135a and 199a-5p. J Immunol 2010, 184:3878-3888.
28. Kuvibidila S., Gardner R., Ode D., Yu L., Lane G., Warrier R.P. Tumor necrosis factor alpha in children with sickle cell disease in stable condition. J Natl Med Assoc 1997, 89:609-615.
29. Taylor S.C., Shacks S.J., Qu Z. In vivo production of type 1 cytokines in healthy sickle cell disease patients. J Natl Med Assoc 1999, 91:619-624.
30. Taylor S.C., Shacks S.J., Villicana S.M., Olivares J., Dinkins G.A. Interferon production in sickle cell disease. Lymphokine Res 1990, 9:415-423.
31. Steinberg M.H., Adewoye A.H. Modifier genes and sickle cell anemia. Curr Opin Hematol 2006, 13:131-136.
32. Darbari D.S., Onyekwere O., Nouraie M., et al. Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. J Pediatr 2012, 160:286-290.
33. Veiga P.C., Schroth R.J., Guedes R., Freire S.M., Nogueira-Filho G. Serum cytokine profile among Brazilian children of African descent with periodontal inflammation and sickle cell anaemia. Arch Oral Biol 2013, 58:505-510.
34. Crawley J.B., Williams L.M., Mander T., Brennan F.M., Foxwell B.M. Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the anti-inflammatory effects of the cytokine. J Biol Chem 1996, 271(27):16357-16362.
35. Strle K., Zhou J.H., Broussard S.R., Venters H.D., Johnson R.W., Freund G.G., Dantzer R., Kelley K.W. IL-10 promotes survival of microglia without activating Akt. J Neuroimmunol 2002, 122:9-19.
36. Rajasingh J., Bord E., Luedemann C., Asai J., Hamada H., Thorne T., et al. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. FASEB J 2006, 20:2112-2114.